Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Mar 26, 2012
SAN DIEGO, March 26, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in p...
Mar 14, 2012
SAN DIEGO, March 14, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2011, and reviewed recent developments. "Lorcaserin has the potential to be an important option for physicians to address the medical management of obesity, helping patients...
Mar 8, 2012
SAN DIEGO, March 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will report fourth quarter and full year 2011 financial results after the NASDAQ Global Select Market closes on Wednesday, March 14, 2012. That same afternoon, Arena's President and Chief Executive Officer, Jack Lief, will host a conference c...
Mar 2, 2012
SAN DIEGO, March 2, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the filing of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who ar...
Feb 23, 2012
SAN DIEGO, Feb. 23, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Citi 2012 Global Health Care Conference on Wednesday, February 29, 2012, at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time) at the Waldorf=Astoria in New York City. Jack Lief, Arena's President and Chi...
Feb 8, 2012
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Jack Lief, Arena's President and Chief Executive Officer, and Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, are scheduled to present a corporate overview and update at two upcoming investor conferences at th...
Feb 1, 2012
SAN DIEGO, and WOODCLIFF LAKE, N.J., Feb. 1, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified Arena that an Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the lorcaserin New Drug Application (NDA) resubmission will be ...
Jan 11, 2012
SAN DIEGO, Jan. 11, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it has agreed to sell 9,953,250 shares of its common stock, at a price of $1.65775 per share, and approximately 9,953 shares of its Series D Convertible Preferred Stock, at a price of $1,657.75 per share, in a registered direct public offering t...
Jan 10, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has accepted for filing and review Arena's resubmission of the New Drug Application (NDA) for lorcaserin. The FDA considers the resubmission a complete, class 2 re...
Jan 5, 2012
SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at The Westin St. Francis in San Francisco, California. Jack Lief, Arena's...
Jan 3, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 3, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that Arena has submitted its response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) following review of the lorcaserin New Drug Application (NDA). Lorcaserin is intend...
Dec 8, 2011
SAN DIEGO, Dec. 8, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011, at 10:15 a.m. Eastern Time (7:15 a.m. Pacific Time) at the Waldorf=Astoria in New York City. Jack Lief, Arena's President an...
Nov 23, 2011
SAN DIEGO, Nov. 23, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Piper Jaffray 23rd Annual Health Care Conference on Wednesday, November 30, 2011, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) at The New York Palace in New York City. Jack Lief, Arena's President...
Nov 9, 2011
SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the third quarter ended September 30, 2011. "We are focused on submitting our response to the FDA for the lorcaserin complete response letter around year-end and filing the lorcaserin marketing authorization application with th...
Nov 3, 2011
SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will report third quarter 2011 financial results after the NASDAQ Global Select Market closes on Wednesday, November 9, 2011. The next morning, November 10, 2011, Arena's President and Chief Executive Officer, Jack Lief, will host a conference...
= add release to Briefcase